J.J. Hsieh, M.P. Purdue, S. Signoretti, C. Swanton, L. Albiges, M. Schmidinger, D.Y. Heng, J. Larkin, and V. Ficarra, Renal cell carcinoma. Nat Rev Dis Primers 3 (2017) 17009.
 B.A. Inman, M.R. Harrison, and D.J. George, Novel immunotherapeutic strategies in development for renal cell carcinoma. Eur Urol 63 (2013) 881-9.
 M. Meskawi, M. Sun, Q.D. Trinh, M. Bianchi, J. Hansen, Z. Tian, M. Rink, S. Ismail, S.F. Shariat, F. Montorsi, P. Perrotte, and P.I. Karakiewicz, A review of integrated staging systems for renal cell carcinoma. Eur Urol 62 (2012) 303-14.
 I. Wolff, M. May, B. Hoschke, R. Zigeuner, L. Cindolo, G. Hutterer, L. Schips, O. De Cobelli, B. Rocco, C. De Nunzio, A. Tubaro, I. Coman, B. Feciche, M. Truss, O. Dalpiaz, R.S. Figenshau, K. Madison, M. Sanchez-Chapado, M.D. Santiago Martin, L. Salzano, G. Lotrecchiano, S.F. Shariat, M. Hohenfellner, R. Waidelich, C. Stief, K. Miller, S. Pahernik, S. Brookman-May, C.P. Members of the, and G. the European Association of Urology Young Academic Urologists Renal Cancer, Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database. Eur J Surg Oncol 42 (2016) 744-50.
 J.J. Hsieh, V. Le, D. Cao, E.H. Cheng, and C.J. Creighton, Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision. J Pathol 244 (2018) 525-537.
 C.J. Ricketts, A.A. De Cubas, H. Fan, C.C. Smith, M. Lang, E. Reznik, R. Bowlby, E.A. Gibb, R. Akbani, R. Beroukhim, D.P. Bottaro, T.K. Choueiri, R.A. Gibbs, A.K. Godwin, S. Haake, A.A. Hakimi, E.P. Henske, J.J. Hsieh, T.H. Ho, R.S. Kanchi, B. Krishnan, D.J. Kwiatkowski, W. Lui, M.J. Merino, G.B. Mills, J. Myers, M.L. Nickerson, V.E. Reuter, L.S. Schmidt, C.S. Shelley, H. Shen, B. Shuch, S. Signoretti, R. Srinivasan, P. Tamboli, G. Thomas, B.G. Vincent, C.D. Vocke, D.A. Wheeler, L. Yang, W.Y. Kim, A.G. Robertson, N. Cancer Genome Atlas Research, P.T. Spellman, W.K. Rathmell, and W.M. Linehan, The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep 23 (2018) 313-326 e5.
 T.W. Nilsen, and B.R. Graveley, Expansion of the eukaryotic proteome by alternative splicing. Nature 463 (2010) 457-63.
 F.E. Baralle, and J. Giudice, Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol 18 (2017) 437-451.
 Y. Wang, J. Liu, B.O. Huang, Y.M. Xu, J. Li, L.F. Huang, J. Lin, J. Zhang, Q.H. Min, W.M. Yang, and X.Z. Wang, Mechanism of alternative splicing and its regulation. Biomed Rep 3 (2015) 152-158.
 L.M. Gallego-Paez, M.C. Bordone, A.C. Leote, N. Saraiva-Agostinho, M. Ascensao-Ferreira, and N.L. Barbosa-Morais, Alternative splicing: the pledge, the turn, and the prestige : The key role of alternative splicing in human biological systems. Hum Genet 136 (2017) 1015-1042.
 N. Martinez-Montiel, N.H. Rosas-Murrieta, M. Anaya Ruiz, E. Monjaraz-Guzman, and R. Martinez-Contreras, Alternative Splicing as a Target for Cancer Treatment. Int J Mol Sci 19 (2018).
 J. Chen, and W.A. Weiss, Alternative splicing in cancer: implications for biology and therapy. Oncogene 34 (2015) 1-14.
 A.R. Kornblihtt, I.E. Schor, M. Allo, G. Dujardin, E. Petrillo, and M.J. Munoz, Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol 14 (2013) 153-65.
 X. Song, Z. Zeng, H. Wei, and Z. Wang, Alternative splicing in cancers: From aberrant regulation to new therapeutics. Semin Cell Dev Biol 75 (2018) 13-22.
 Y.S. Tsai, D. Dominguez, S.M. Gomez, and Z. Wang, Transcriptome-wide identification and study of cancer-specific splicing events across multiple tumors. Oncotarget 6 (2015) 6825-39.
 E. Sebestyen, M. Zawisza, and E. Eyras, Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer. Nucleic Acids Res 43 (2015) 1345-56.
 K. Tomczak, P. Czerwinska, and M. Wiznerowicz, The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn) 19 (2015) A68-77.
 A. Colaprico, T.C. Silva, C. Olsen, L. Garofano, C. Cava, D. Garolini, T.S. Sabedot, T.M. Malta, S.M. Pagnotta, I. Castiglioni, M. Ceccarelli, G. Bontempi, and H. Noushmehr, TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res 44 (2016) e71.
 M.C. Ryan, J. Cleland, R. Kim, W.C. Wong, and J.N. Weinstein, SpliceSeq: a resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts. Bioinformatics 28 (2012) 2385-7.
 M. Ryan, W.C. Wong, R. Brown, R. Akbani, X. Su, B. Broom, J. Melott, and J. Weinstein, TCGASpliceSeq a compendium of alternative mRNA splicing in cancer. Nucleic Acids Res 44 (2016) D1018-22.
 O. Troyanskaya, M. Cantor, G. Sherlock, P. Brown, T. Hastie, R. Tibshirani, D. Botstein, and R.B.J.B. Altman, Missing value estimation methods for DNA microarrays. 17 520-525.
 J.R. Conway, A. Lex, and N. Gehlenborg, UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics 33 (2017) 2938-2940.
 G. Yu, L.G. Wang, Y. Han, and Q.Y. He, clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16 (2012) 284-7.
 J.H. Friedman, T. Hastie, and R.J.J.o.S.S. Tibshirani, Regularization Paths for Generalized Linear Models via Coordinate Descent. 033 (2010).
 N. Simon, J. Friedman, T. Hastie, and R. Tibshirani, Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. J Stat Softw 39 (2011) 1-13.
 P. Blanche, J.F. Dartigues, and H. Jacqmin-Gadda, Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med 32 (2013) 5381-97.
 V.P. Balachandran, M. Gonen, J.J. Smith, and R.P. DeMatteo, Nomograms in oncology: more than meets the eye. The Lancet Oncology 16 (2015) e173-e180.
 A. Iasonos, D. Schrag, G.V. Raj, and K.S. Panageas, How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 26 (2008) 1364-70.
 E.W. Steyerberg, and A.J. Vickers, Decision curve analysis: a discussion. Med Decis Making 28 (2008) 146-9.
 A.J. Vickers, and E.B. Elkin, Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 26 (2006) 565-74.
 B. Van Calster, L. Wynants, J.F.M. Verbeek, J.Y. Verbakel, E. Christodoulou, A.J. Vickers, M.J. Roobol, and E.W. Steyerberg, Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators. Eur Urol 74 (2018) 796-804.
 M. Fitzgerald, B.R. Saville, and R.J.J.J.J.o.t.A.M.A. Lewis, Decision Curve Analysis. 313 (2015) 409-10.
 S. Aravind, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. %J Proceedings of the National Academy of Sciences of the United States of America. 43 (2005).
 A. Liberzon, C. Birger, H. Thorvaldsdottir, M. Ghandi, J.P. Mesirov, and P. Tamayo, The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst 1 (2015) 417-425.
 F. Piva, M. Giulietti, A.B. Burini, and G. Principato, SpliceAid 2: a database of human splicing factors expression data and RNA target motifs. Hum Mutat 33 (2012) 81-5.
 Y. Xiong, Y. Deng, K. Wang, H. Zhou, X. Zheng, L. Si, and Z. Fu, Profiles of alternative splicing in colorectal cancer and their clinical significance: A study based on large-scale sequencing data. EBioMedicine 36 (2018) 183-195.
 M.I. Love, W. Huber, and S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15 (2014) 550.
 Y. Ge, N. Weygant, D. Qu, R. May, W.L. Berry, J. Yao, P. Chandrakesan, W. Zheng, L. Zhao, K.L. Zhao, M. Drake, K.J. Vega, M.S. Bronze, J.J. Tomasek, G. An, and C.W. Houchen, Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Int J Cancer 143 (2018) 1162-1175.
 D.J.C.R. Bates, VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. 62 (2002).
 J. Jiang, X. Chen, H. Liu, J. Shao, R. Xie, P. Gu, and C. Duan, Polypyrimidine Tract-Binding Protein 1 promotes proliferation, migration and invasion in clear-cell renal cell carcinoma by regulating alternative splicing of PKM. 7 (2017) 245.
 K. Chen, H. Xiao, J. Zeng, G. Yu, H. Zhou, C. Huang, W. Yao, W. Xiao, J. Hu, W. Guan, L. Wu, J. Huang, Q. Huang, H. Xu, and Z. Ye, Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer. Clin Cancer Res 23 (2017) 3428-3441.
 C. Bianchi, S. Bombelli, F. Raimondo, B. Torsello, V. Angeloni, S. Ferrero, V. Di Stefano, C. Chinello, I. Cifola, L. Invernizzi, P. Brambilla, F. Magni, M. Pitto, G. Zanetti, P. Mocarelli, and R.A. Perego, Primary cell cultures from human renal cortex and renal-cell carcinoma evidence a differential expression of two spliced isoforms of Annexin A3. Am J Pathol 176 (2010) 1660-70.
 X. Feng, L. Zhang, W. Tu, and S. Cang, Frequency, incidence and survival outcomes of clear cell renal cell carcinoma in the United States from 1973 to 2014: A SEER-based analysis. Medicine (Baltimore) 98 (2019) e16684.
 M.B. Atkins, and N.M. Tannir, Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev 70 (2018) 127-137.
 M. Qu, J. Yu, H. Liu, Y. Ren, C. Ma, X. Bu, and Q. Lan, The Candidate Tumor Suppressor Gene SLC8A2 Inhibits Invasion, Angiogenesis and Growth of Glioblastoma. Mol Cells 40 (2017) 761-772.
 P. Lin, R.Q. He, F.C. Ma, L. Liang, Y. He, H. Yang, Y.W. Dang, and G. Chen, Systematic Analysis of Survival-Associated Alternative Splicing Signatures in Gastrointestinal Pan-Adenocarcinomas. EBioMedicine 34 (2018) 46-60.
 J. Zhu, Z. Chen, and L. Yong, Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer. Gynecol Oncol 148 (2018) 368-374.
 K.V. Lehmann, A. Kahles, C. Kandoth, W. Lee, and G.J.P.S.o.B.P.S.o.B. Rätsch, Integrative genome-wide analysis of the determinants of RNA splicing in kidney renal clear cell carcinoma. 20 (2014) 44-55.
 C.W. Yun, and S.H. Lee, The Roles of Autophagy in Cancer. Int J Mol Sci 19 (2018).
 P. Rajendran, A.M. Alzahrani, H.N. Hanieh, S.A. Kumar, R. Ben Ammar, T. Rengarajan, and M.A. Alhoot, Autophagy and senescence: A new insight in selected human diseases. J Cell Physiol 234 (2019) 21485-21492.
 D.P. Hall, N.G. Cost, S. Hegde, E. Kellner, O. Mikhaylova, Y. Stratton, B. Ehmer, W.A. Abplanalp, R. Pandey, J. Biesiada, C. Harteneck, D.R. Plas, J. Meller, and M.F. Czyzyk-Krzeska, TRPM3 and miR-204 establish a regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma. Cancer Cell 26 (2014) 738-53.
 A. Mizutani, D. Koinuma, H. Seimiya, and K. Miyazono, The Arkadia-ESRP2 axis suppresses tumor progression: analyses in clear-cell renal cell carcinoma. Oncogene 35 (2016) 3514-23.
 B. Carpenter, C. MacKay, A. Alnabulsi, M. MacKay, C. Telfer, W.T. Melvin, and G.I. Murray, The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta 1765 (2006) 85-100.
 M. Rydzanicz, T. Wrzesinski, H.A. Bluyssen, and J. Wesoly, Genomics and epigenomics of clear cell renal cell carcinoma: recent developments and potential applications. Cancer Lett 341 (2013) 111-26.